From Pandemic Suspect to the Postvaccine Era: The Haemophilus influenzae
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The history of the gram-negative coccobacillus, now known as Haemophilus influenzae, has several exciting chapters. In the frenzy of microbiologists' quest to identify the etiologic agent responsible for the devastating 1918 pandemic of influenza, the Pfeiffer's bacillus, or Bacillus influenzae, repeatedly occurred in pathology samples obtained from persons who died of fatal respiratory infections [1]. It is ironic that the organism, eventually designated H. influenzae, which was once so widely evident in laboratory tests (albeit, only fleetingly considered the cause of the “Spanish flu”), is now a rarely visible culprit that is still responsible for a huge toll of childhood illness in resource-poor countries. The story in between is one of progress and promise, with near elimination of serotype b disease in the United States and the emergence of new global initiatives for the poorest countries. Dworkin et al. [2], in this issue of Clinical Infectious Diseases, provide a new chapter in the H. influenzae story by describing 9 years of surveillance for invasive H. influenzae disease in Illinois during 1996–2004. In 1987, H. influenzae type b polysaccharide-protein conjugate vaccines were licensed in the United States for children aged ⩾18 months, and before conjugate vaccines were even recommended for infants in the 2, 4, 6–month schedule in October 1990 by the Advisory Committee on Immunization Practices [3], a phenomenal herd effect was already occurring, as children who had been too young to be immunized began to experience significantly lower risk of disease [4]. The epidemiological trends were explained by the vaccine's ability to reduce acquisition of H. influenzae type b colonization, which led to interrupted transmission. The impact on H. influenzae type b disease was also evident among adults, although the vast majority of cases of H. influenzae type b disease had concentrated among children aged <5 years who were the primary beneficiaries of both direct and indirect vaccine effects. The incidence of invasive disease due to H. influenzae type b in the United States decreased by >99% (from >30 cases to <1 case per 100,000 children aged <5 years) [5]. These dramatic effects were replicated in wealthy countries throughout the world. By 1995, routine childhood vaccination against H. influenzae type b disease had reduced all bacterial meningitis by 55% and had shifted the median age of remaining patients from 15 months to 25 years [6]. More recent introduction of polysaccharide-protein conjugate vaccines for pneumococcal and meningococcal disease offers promise for this devastating clinical syndrome to become even rarer. For too many years, progress in the control of H. influenzae type b disease was limited to industrialized countries, because cost of vaccine was an important barrier to widespread uptake. Another barrier was lack of recognition of the pathogen in many countries in which meningitis and sepsis are not routinely evaluated by microbiological testing, and limited resources in laboratories for detection of the organism have further hidden its role. Innovative studies that used the conjugate vaccine as a probe to uncover the preventable burden of H. influenzae type b have now demonstrated the major role that this bacterium plays in childhood meningitis and pneumonia on multiple continents [7,8–9]. There is now financial support for the procurement of the H. influenzae type b vaccine for the world's poorest countries through the Global Alliance for Vaccines and Immunization (GAVI; http://www.gavialliance.org). The H. influenzae type b vaccine has been introduced by 22 GAVI-eligible countries, and many more are requesting the vaccine. Routine childhood vaccination has now led to dramatic decreases in invasive disease in several countries in Africa [10,11–12], including settings with a very high prevalence of HIV infection [13]. In 2005, GAVI funded the Hib Initiative to catalyze support of evidence-based decision-making regarding use of the H. influenzae type b vaccine (http://www.Hibaction.org). In 2006, the World Health Organization updated their position on the H. influenzae type b vaccine in support of global implementation [14]. Although many resource-poor countries still await realization of the benefits of disease prevention through use of the H. influenzae type b conjugate vaccine, the analysis by Dworkin et al. [2] of H. influenzae surveillance trends in Illinois gives a glimpse into the postvaccine era. Using statewide passive reporting complemented by hospital discharge data, Dworkin and colleagues confirm a low incidence of total H. influenzae invasive disease among children aged <5 years, fluctuating between <1 case to nearly 3 cases per 100,000 children; one-fourth of cases in this age group were caused by serotype b. Of interest, Dworkin et al. [2] describe a significant increase in the reporting of invasive H. influenzae disease in people aged ⩾65 years from 1.1 to 3.9 cases per 10
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prior to the availability of H. influenzae type b conjugate vaccines in the United States, H. influenzae accounted for 45 to 48% of all cases of bacterial meningitis (276, 344); it now accounts for only 7% of cases (281, 305).”
From Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis (2010) · cites this paper as [281]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This was accompanied by a change in the mean age of cases of bacterial meningitis, from 15 months of age in 1986 to 25 years of age in 1995, because most cases of H. influenzae meningitis reported prior to vaccination occurred in infants and children aged 6 to 12 months.”
From Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis (2010) · cites this paper as [281]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bacterial Meningitis in the United States in 1995
Schuchat, A., Robinson, K., Wenger, J. D., Harrison, L. H., Farley, M., Reingold, A. L., Lefkowitz, L., & Perkins, B. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710023371404 · Cited by 1,251 · cited 1×
“By 1995, routine childhood vaccination against H. influenzae type b disease had reduced all bacterial meningitis by 55% and had shifted the median age of remaining patients from 15 months to 25 years [ 6 ].”
BackgroundSelf-citationDecline of Childhood Haemophilus influenzae Type b (Hib) Disease in the Hib Vaccine Era
Adams, W. G. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500020055031 · Cited by 696 · cited 1×
“... type b polysaccharide-protein conjugate vaccines were licensed in the United States for children aged 18 months, and before conjugate vaccines were even recommended for infants in the 2, 4, 6–month schedule in October 1990 by the Advisory Committee on Immunization Practices [3], a phenomenal herd effect was alread…”
BackgroundMaternal mortality surveillance, United States, 1980-1985.
Koonin, L. M., Atrash, H. K., Rochat, R. W., & Smith, J. C. (1988) · PubMed · Cited by 509
Mulholland, K., Hilton, S., Adegbola, R., Usen, S., Oparaugo, A., Omosigho, C., Weber, M., Palmer, A., Schneider, G., Jobe, K., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09267-7 · Cited by 406 · cited 1×
“influenzae type b have now demonstrated the major role that this bacterium plays in childhood meningitis and pneumonia on multiple continents [7–9].”
BackgroundPai, R., Moore, M. R., Pilishvili, T., Gertz, R. E., Whitney, C. G., Beall, B., & Active Bacterial Core Surveillance Team (2005) · The Journal of Infectious Diseases · doi:10.1086/498043 · Cited by 330 · cited 1×
“For the pneumococcal conjugate vaccine, emergence of nonvaccine types has started to occur— both among the target age group of young children [19, 20] and among HIV-infected adults [20]—but for both pneumococcal and H.”
BackgroundThe great influenza: the epic story of the deadliest plague in history
(2004) · Choice Reviews Online · doi:10.5860/choice.42-0972 · Cited by 317
Adegbola, R. A., Secka, O., Lahai, G., Lloyd-Evans, N., Njie, A., Usen, S., Oluwalana, C., Obaro, S., Weber, M., Corrah, T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66788-8 · Cited by 286
A Randomized Trial to Reduce Passive Smoke Exposure in Low-Income Households With Young Children
Emmons, K. M., Hammond, S. K., Fava, J. L., Velicer, W. F., Evans, J. L., & Monroe, A. D. (2001) · Pediatrics · doi:10.1542/peds.108.1.18 · Cited by 215
Gessner, B. D., Sutanto, A., Linehan, M., Djelantik, I. G. G., Fletcher, T., Gerudug, I. K., Ingerani, Mercer, D., Moniaga, V., Moulton, L. H., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17664-2 · Cited by 203
Flannery, B., Heffernan, R. T., Harrison, L. H., Ray, S. M., Reingold, A. L., Hadler, J., Schaffner, W., Lynfield, R., Thomas, A. R., Li, J., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-1-200601030-00004 · Cited by 192 · cited 1×
“For the pneumococcal conjugate vaccine, emergence of nonvaccine types has started to occur— both among the target age group of young children [19, 20] and among HIV-infected adults [20]—but for both pneumococcal and H.”
BackgroundSelf-citation
Research works printed but not linked: 6
- Dworkin MS, Park L, Borchardt SM. The changing epidemiology of invasive Haemoph- ilus influenzae disease, especially in persons у65 years. Clin Infect Dis 2007; 44:810-6.
- Centers for Disease Control and Prevention. Haemophilus b conjugate vaccines for preven- tion of Haemophilus influenzae type b disease among infants and children two months of age and older: recommendations of the Im- munization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep 1991; 40:1-7.
- Centers for Disease Control and Prevention. Progress toward elimination of Haemophilus influenzae type b disease among infants and children: United States, 1987-1997. MMWR Morb Mortal Wkly Rep 1998; 47:993-8.
- World Health Organization. WHO position paper on Haemophilus influenzae type b con- jugate vaccines. Bull World Health Organ 2006; 81:445-52.
- Centers for Disease Control and Prevention. Serotyping discrepancies in Haemophilus in- fluenzae type b disease: United States, 1998-1999. MMWR Morb Mortal Wkly Rep 2002; 51:706-7.
- Ribeiro GS, Reis JN, Cordeiro SM, et al. Pre- vention of Haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after intro- duction of Hib immunization in Brazil. J In- fect Dis 2003; 187:109-16.
Cited by
Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis
Brouwer, M. C., Tunkel, A. R., & van de Beek, D. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00070-09 · Cited by 930
Summary of Notifiable Infectious Diseases and Conditions — United States, 2015
Adams, D. A., Thomas, K. R., Jajosky, R. A., Foster, L., Baroi, G., Sharp, P., Onweh, D. H., Schley, A. W., Anderson, W. J., & for the Nationally Notifiable Infectious Conditions Group (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6453a1 · Cited by 180
von Gottberg, A., Cohen, C., Whitelaw, A. C., Chhagan, M. K., Flannery, B. L., Cohen, A. L., de Gouveia, L., du Plessis, M., Madhi, S. A., & Klugman, K. P. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.11.066 · Cited by 36
Community-acquired Haemophilus influenzae pneumonia – New insights from the CAPNETZ study
Forstner, C., Rohde, G. G. U., Rupp, J., Schuette, H., Ott, S. R., Hagel, S., Harrison, N. M., Thalhammer, F., von Baum, H., Suttorp, N., et al. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.02.010 · Cited by 31
Roos, K. L., & van de Beek, D. (2010) · Handbook of clinical neurology · doi:10.1016/s0072-9752(09)96004-3 · Cited by 29
Metadata
- Authors
- Schuchat, A., & Messonnier, N. R.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Schuchat, A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-03-15
- Volume
- 44
- Issue
- 6
- Pages
- 817-819
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2088566705
- Cited by
- 10
- References
- 19
- Citations by year
- 2021: 1 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Keywords
- Haemophilus influenzae type b, Haemophilus influenzae type f, Haemophilus influenzae type a
- MeSH terms
- Disease Outbreaks, Female, Haemophilus Infections, Haemophilus influenzae, Humans, Male, Prognosis, Vaccination, Incidence, Survival Rate, Haemophilus Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.